Exceptionally Potent Chiral Anandamide Analogs.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Endocannabinoids are crucial signaling molecules in the central nervous system.
• Existing endocannabinoids like N-arachidonoylethanolamide and 2-arachidonoylglycerol have limited metabolic stability.
• Previous work introduced chiral centers to enhance endocannabinoid stability, leading to AMG315.

Purpose of the Study:

• To synthesize and optimize tail-modified analogs of AMG315.
• To improve binding affinity and potency at cannabinoid receptors.
• To develop a novel endocannabinoid probe for research.

Main Methods:

• Synthesis of tail-modified analogs based on AMG315.
• In vitro functional characterization of receptor binding and activity.
• In vivo testing for potency and efficacy.
• Molecular docking studies against CB1 and CB2 receptor crystal structures.

Main Results:

• Identified AM12814 (20,20,20-trifluoro-(R)-N-(1-methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide) as a lead compound.
• AM12814 demonstrated unprecedented affinity for both CB1 and CB2 receptors.
• In vitro, AM12814 acted as a potent, partial agonist at CB1 and CB2 receptors.
• In vivo, AM12814 proved to be a highly potent and efficacious CB1 agonist.

Conclusions:

• Tail modification of AMG315 led to the discovery of AM12814, a potent dual CB1/CB2 receptor agonist.
• AM12814 exhibits superior affinity and efficacy compared to previous analogs.
• This novel compound serves as a valuable tool for investigating the endocannabinoid system.